Follow us...

 

Search News Archives

Monthly Newsletter

 

Lab Bulletin August Newsletter

view the latest issue

Subscribe

News Channels

 

New Laboratory Products

 

Lab News

 

Microscopy & Image Analysis

 

Separation Science

 

Research & Case Studies

 

Literature

 

Videos

 

Events | Webinars

 

 

 

Conferences | Events

Innova Biosciences and Mologic Sign Supply and Licensing Agreement

publication date: Aug 26, 2015
 | 
author/source: Innova Biosciences

License covers use of Innova’s Lightning-Link and InnovaCoat GOLD technologies in Mologic’s kits and services

innova biosciencesInnova Biosciences (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use of Innova’s Lightning-Link® and InnovaCoat® GOLD technologies as part of Mologic’s commercial assay development services and range of immunoassays.

The deal provides Mologic with rights to incorporate Innova Technology into its products, including its full point of care diagnostic portfolio in addition to its B.I.T.S.™ range of high quality laboratory diagnostic assays.  The agreement also allows Mologic to provide its customers direct access to Innova’s leading technology when incorporated into product development programmes.

Lightning-Link is the fastest, easiest to use, most efficient antibody conjugation method available. Requiring only 30 seconds hands-on time, with no separation steps and 100% antibody recovery, Lightning-Link provides highly stable conjugates due to its covalent bonding mechanism.

InnovaCoat GOLD is a one-step kit for conjugation of antibodies, proteins and peptides or any other biomolecule with an amine group, using gold nanoparticles. The superior quality gold nanoparticles have a proprietary surface coating, which enhances colloidal stability and enables covalent linking of the nanoparticle to an antibody.

Dr Nick Gee, CEO of Innova Biosciences, commented: “We are delighted to sign this agreement with Mologic, which forms part of our strategy of working with high-quality partners. The Company has an excellent reputation in immunoassay development, and we see their decision to work with Lightning-Link and InnovaCoat GOLD as a powerful endorsement of our technologies.”

Mark Davis, CEO of Mologic, said: “We have already benefitted from using Innova’s conjugation technology and have seen excellent results across the product range.  The simplicity of Lightning-Link kits has led to them becoming essential tools for our highly efficient research group. Extending the relationship to a formal supply and licensing agreement will enable us to continue using the technologies in assay development, and as part of our custom services and disruptive product pipeline. We look forward to working with Innova further.”

Innova’s bioconjugation technologies have a wide range of applications across biological research, and in the development and manufacturing of diagnostic kits. The expanding portfolio is supplied to research laboratories, pharmaceutical companies, biotechnology companies and diagnostic companies worldwide.


more about innova biosciences


 



 

 

Popular this Month...

Our Top 10 most popular articles this month

 

Today's Picks...

 

 


 

Looking for a Supplier?

Search by company or by product

 


Company Name:

Product:


 

 

Please note Lab Bulletin does not sell, supply any of the products featured on this website. If you have an enquiry, please use the contact form below the article or company profile and we will send your request to the supplier so that they can contact you directly.

Lab Bulletin is published by newleaf marketing communications ltd

 


Promotions

 

Media Partners